An observational study recently published in Cancer highlights a notable correlation between glucose-6-phosphate dehydrogenase (G6PD) deficiency and improved clinical outcomes among patients with ...

Like many cancers, acute myeloid leukemia (AML) has been a major beneficiary from the introduction of targeted therapies into the oncology treatment landscape. In fact, 1 of the earliest uses of ...

This treatment is used to treat a type of blood cancer called acute myeloid leukaemia (AML). It is best to read this information with our general information about cancer drug treatments and the type ...

Kura Oncology, Inc. (NASDAQ:KURA) Q3 2025 Earnings Call Transcript November 4, 2025 Kura Oncology, Inc. misses on earnings expectations. Reported EPS is $-0.84564 EPS, expectations were $-0.57.

ORLANDO -- Azacitidine and venetoclax (Venclexta) significantly improved event-free survival (EFS) in newly diagnosed fit adults with acute myeloid leukemia (AML) compared with conventional induction ...

Please provide your email address to receive an email when new articles are posted on . A 5-day azacitidine course had the most consistent survival benefit for low-risk MDS vs. other shorter ...

Dr. Daniel Peters discussed targeted therapies and regimens that patients with acute myeloid leukemia, or AML, should be aware of. During a recent visit to the Georgia Cancer Center, CURE sat down for ...

– New Drug Application for ziftomenib in adults with R/R NPM1-m AML remains under FDA Priority Review, with a PDUFA target action date of November 30, 2025 – – KOMET 017 Phase 3 trials to evaluate ...

Overall response rates in the azacitidine plus venetoclax, chemotherapy, and azacitidine monotherapy groups were 38.5%, 20.0%, and 6.7%, respectively. Although some younger, fitter patients may be ...

The evolving treatment landscape for unfit patients with newly diagnosed acute myeloid leukemia (AML) centers on venetoclax combination and personalized strategies. Management of newly diagnosed acute ...